Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 334 |
| Active Pipeline (Recruiting Now) | 146 (77) |
| Completed vs Stopped Early | 156 / 32 (9.6%) |
| Median Closed Actual Enrollment | 312 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 88 (16 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | 56 |
| National Taiwan University Hospital | Taipei | 56 |
| Severance Hospital, Yonsei University Health System | Seoul, Other | 53 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Phase III | RECRUITING |
| NCT07613294 | A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High | Phase III | RECRUITING |
| NCT07219953 | A Study of Brenipatide in Participants With Alcohol Use Disorder | Phase III | RECRUITING |
| NCT07589608 | A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Ov | Phase II | RECRUITING |
| NCT05254743 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Eli Lilly and Company Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.